Study to Determine Maximum Tolerated Dose of LErafAON Combined With Radiotherapy in Patients With Advanced Malignancies
- Conditions
- Neoplasms
- First Posted Date
- 2001-09-25
- Last Posted Date
- 2011-04-13
- Lead Sponsor
- INSYS Therapeutics Inc
- Target Recruit Count
- 25
- Registration Number
- NCT00024648
- Locations
- ๐บ๐ธ
Georgetown University, Washington, District of Columbia, United States
๐บ๐ธUniversity of Chicago Medical Center, Chicago, Illinois, United States
๐บ๐ธFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses
- Conditions
- Neoplasms
- First Posted Date
- 2001-09-25
- Last Posted Date
- 2014-11-14
- Lead Sponsor
- INSYS Therapeutics Inc
- Registration Number
- NCT00024687
- Locations
- ๐บ๐ธ
NCI/NIH, Bethesda, Maryland, United States
Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients
- Conditions
- Malignant GliomaGlioblastoma MultiformeAnaplastic AstrocytomaMixed OligoastrocytomaMalignant Astrocytoma
- First Posted Date
- 2001-09-21
- Last Posted Date
- 2011-06-06
- Lead Sponsor
- INSYS Therapeutics Inc
- Target Recruit Count
- 40
- Registration Number
- NCT00024557
- Locations
- ๐บ๐ธ
University of California San Francisco, San Francisco, California, United States
๐บ๐ธYale University, New Haven, Connecticut, United States
๐บ๐ธMemorial Sloan-Kettering Cancer Center, New York, New York, United States
Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma
- Conditions
- Anaplastic AstrocytomaGlioblastoma MultiformeMixed OligoastrocytomaMalignant Glioma
- First Posted Date
- 2001-09-21
- Last Posted Date
- 2014-11-14
- Lead Sponsor
- INSYS Therapeutics Inc
- Target Recruit Count
- 60
- Registration Number
- NCT00024570
- Locations
- ๐บ๐ธ
University of Alabama at Birmingham, Birmingham, Alabama, United States
๐บ๐ธH. Lee Moffitt Cancer Center, Tampa, Florida, United States
๐บ๐ธEmory University, Atlanta, Georgia, United States
Study of Liposome Encapsulated Mitoxantrone (LEM) in Patients With Advanced Cancer
- Conditions
- Tumors
- First Posted Date
- 2001-09-18
- Last Posted Date
- 2011-06-06
- Lead Sponsor
- INSYS Therapeutics Inc
- Target Recruit Count
- 40
- Registration Number
- NCT00024492
- Locations
- ๐บ๐ธ
City of Hope National Medical Center, Duarte, California, United States
๐บ๐ธH. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
๐บ๐ธBarbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States